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INTRODUCTION
 Graves’ disease (GD) is an autoimmune thyroid 
disorder characterized by thyrotoxicosis, frequent 
infiltrative orbitopathy, and occasional infiltrative 
dermopathy.1-3 Thyrotoxicosis can cause some alter-
ations in various body systems. In the hematopoiet-
ic system, red blood cell mass is increased due to the 
direct effect of thyroid hormones on the erythroid 
marrow and increased erythropoietin production. 
Platelet levels and intrinsic clotting mechanism are 
normal, but the concentration of factor VIII is often 
increased.4,5 Additionally, an increase in megakary-
ocytes and a decrease in platelet survival time can 
be observed in hyperthyroid patients.
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ABSTRACT
Objective: To evaluate the impact of mean platelet volume (MPV) on predicting disease course among 
patients with Graves’ disease (GD).
Methods: This retrospective study was performed between 2013-2016 at the Outpatient Endocrinology 
Clinic of Baskent University Faculty of Medicine, Adana hospital on 65 patients with GD. Among participants, 
30 cases experienced thyrotoxicosis again during the first six months after discontinuing anti-thyroid drug 
(ATD) sessions that had been carried out for at least 12 months prior to stopping (Relapse group). We also 
observed 35 patients who exhibited normal thyroid functions within six months following ATD withdrawal 
(Remission group). MPV levels and thyroid function tests were recorded and total duration of ATD therapy 
was calculated for all participants.
Results: The mean MPV level that was measured at the time of drug withdrawal did not differ between 
groups, being 8.0±1.2 fL in the Relapse group vs. 8.0±1.0 fL in the Remission group (p=0.81). However, we 
found that the relapse MPV was higher than the withdrawal MPV in the Relapse group (9.2±1.3 fL) than it 
was in the Remission group (8.0±1.2 fL, p=0.00).
Conclusions: Higher relapse MPV in Relapse group but similar MPV levels in both groups at ATD withdrawal 
may be attributed to hypermetabolism or hyperthyroidism rather than autoimmunity of GD. 
KEYWORDS: Autoimmunity, Graves’ disease, Mean platelet volume.
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BMI: Body mass index. GD: Graves’ disease. MPV: Mean platelet volume. 
TSH: Thyroid-stimulating hormone. TRAbs: Thyrotropin receptor antibodies.
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 There are three effective therapeutic options for GD: 
anti-thyroid drug (ATD), surgery and radioactive 
iodine therapy. Since there is no definitive conclusion 
as to which option is most effective, physician and 
patient preferences often dictate the choice. Anti-
thyroid drugs may alter the course of autoimmune 
process, but the optimal duration of treatment using 
them has not been clearly determined. A long term 
medical therapy lasting at least 12 months is usually 
administered and then withdrawn if serum thyroid 
stimulating hormone (TSH) levels return to normal.6 
The average rate of remission is between 30% and 
50% after ATD withdrawal.2,7
 The course of GD is variable. In some patients, 
thyrotoxicosis persists, while it exhibits remission 
after ATD withdrawal in others. About 75% of 
relapses occur during the first three months after 
drug withdrawal, with most of the remainder 
occurring during the subsequent 6 months.8
 There are some factors that may predict 
the outcome of GD after drug withdrawal. 
For example, the severity of hyperthyroidism at 
initial diagnosis is associated with higher relapse 
rates. Levels of thyrotropin receptor antibodies 
(TRAbs) are decreased by medical treatment but 
may predict recurrence if they persist during this 
regimen. Additionally, remission rates are reported 
to be lower in men, younger patients, smokers and 
patients with larger goiter size and ophthalmopathy 
upon diagnosis.9-12
 Mean platelet volume (MPV) is a machine-
calculated measurement of the average size of 
platelets that can be used to determine platelet 
production and destruction rate in bone marrow. 
Inflammation acts an important stimulant for 
platelets; consequently, large platelets that release a 
variety of pro-inflammatory and thrombotic factors 
are more active. We can therefore consider MPV 
to be a simple sign of subclinical inflammation, 
and it also has been reported to be a marker of 
inflammatory disease activity.13-14
 In this study, we aimed to investigate the relation-
ship between MPV and disease course in patients 
with GD. We also inquired into the association be-
tween treatment outcome and clinical and other 
laboratory variables. After careful consideration of 
these factors, we proposed that MPV measured at 
ATD withdrawal will be higher in relapse GD.
METHODS
 This retrospective study was performed at the 
Outpatient Endocrinology Clinic of Baskent Univer-
sity Faculty of Medicine, Adana hospital between 
the years 2013 and 2016. The medical records of GD 
patients who were followed up at least six months 
after discontinuing a minimum one year course of 
ATD treatment were recruited to the study. All par-
ticipants were euthyroid at ATD withdrawal.
 The diagnosis of GD was based on standard 
clinical and laboratory criteria, including clinical 
symptoms of hyperthyroidism, thyroid ultrasound 
findings, increased concentrations of free thyroxine 
(fT4), free triiodothyronine (fT3) and suppressed 
TSH concentrations in all patients. Additionally, 
measurement of TRAbs, determination of high 
radioactive iodine uptake and/or diffuse uptake 
at thyroid scintigraphy were performed in some 
patients.6 All ATD treatment data was recorded 
from medical documents. 
 Our study excluded Graves’ disease patients 
with known histories of the following conditions: 
cirrhosis, chronic kidney disease, cancer, 
cardiovascular disease, diabetes mellitus, and 
severe obesity (body mass index (BMI)>35kg/
m2), infections, chronic inflammatory diseases that 
include collagen tissue disease and inflammatory 
bowel disease, haematological diseases that include 
haemoglobinopathy, and blood coagulation 
disorders. Furthermore, patients undergoing 
treatment with diuretics, antihyperlipidemic 
agents, anticoagulants, and corticosteroids were 
excluded. Smokers were also excluded.
 All patients were treated with propylthiouracil or 
methimazole by a dose titration regimen. According 
to disease course, patients were divided into two 
groups, the Relapse and Remission groups. Relapse 
group patients experienced thyrotoxicosis again 
during the first six months after discontinuation of 
at least 12 months of ATD sessions. The Remission 
group consisted of GD patients who exhibited 
normal thyroid functions within six months 
following ATD withdrawal, as mentioned above. 
 Serum TSH, fT4, fT3 and MPV levels were record-
ed at the time of ATD withdrawal and relapse in the 
Relapse group and at the time of drug withdrawal 
in the Remission group. The total duration of ATD 
therapies was calculated, as well.The study was ap-
proved by the Local Ethics Committee of Baskent 
University, (Project no: KA 15/385).
Laboratory Analysis: In order to measure each 
participant’s complete blood count (CBC), a venous 
blood sample was obtained and collected in K- 
ethylenediaminetetraacetic acid (EDTA) tubes and 
measured by Siemens Advia 2120i Haematology 
System (Siemens Healthcare Inc. Tarrytown, NY 
USA). The MPV measurements were performed 
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immediately in our laboratory with a reference 
value for MPV of 7.2-11.1 fL. Automated 
chemiluminescent immunoassays performed by the 
Advia Centaur XP Immunoassay system (Siemens 
Healthcare İnc. Tarrytown, NY USA) were used to 
measure fT4 (normal range:11.5-22.7 pmol/L), fT3 
(normal range:3.5-6.5 pmol/L) and TSH (normal 
range:0.4-4.6 uIU/ml).
Statistical Methods: Statistical analysis was 
performed using the statistical package SPSS 
software (Version 17.0, SPSS Inc., and Chicago, IL, 
USA). If continuous variables were normal, they 
were described as the mean±standard deviation 
(p>0.05 in Kolmogorov-Smirnov test or Shapira-
Wilk (n<30)); however, if the continuous variables 
were not normal, they were described as the 
median. Groups of normally distributed data were 
compared using Student T test or One Way ANOVA 
for normally distributed data, while Mann Whitney 
U test or Kruscall Wallis tests were used for groups 
of data not normally distributed. The categorical 
variables between the groups were analysed using 
the Chi square test or Fisher Exc. test.   Pre-post 
measures data were analysed using the Paired 
T test or Wilcoxson test. Values of p<0.05 were 
considered statistically.
RESULTS
 Sixty-five cases were recruited from 245 GD 
patients depending on the excluding criteria 
previously mentioned. The Relapse group contained 
30 patients, while the Remission group was made 
up of 35 patients. The general characteristics of 
the patients are shown in Table-I. Significant 
differences among the groups did not exist in terms 
of age, gender or body mass index (BMI). The mean 
duration of total ATD therapy was calculated as 
22±7.8 months in the Relapse group and 16.6±3.1 
months in the Remission group. Our findings 
showed that the therapy duration was significantly 
shorter in remission group (p=0.00). 
 According to our findings, the mean MPV level 
measured at the time of drug withdrawal did 
not differ between groups, being 8.0±1.2 fL in the 
Relapse group and 8.0±1.0 fL in the Remission group 
(p=0.81). The mean TSH level that was measured 
at the time of drug withdrawal was higher in the 
Remission group at 2.0±1.0, as opposed to 1.5±1.0 
uIU/ml in the Relapse group (p=0.03, Table-II). We 
found that the relapse MPV was higher than the 
withdrawal MPV in the Relapse group at 9.2±1.3 fL 
vs 8.0±1.2 fL, p=0.00, respectively. Even though the 
relapse group had higher relapse MPV values, most 
of them were within the normal limits. Only two 
(6.6%) were above limits. Additionally, the Relapse 
group had a statistically higher relapse MPV than 
the withdrawal MPV of the Remission group at 
9.2±1.3 vs 8.0±1.0 (p=0.00, Table-III). 
DISCUSSION
 Mean platelet volume (MPV) is an automated 
measurement of average size of platelets in whole 
blood that adds no extra cost or effort to a full 
blood count. The positive relationship between 
MPV and inflammation has been shown many 
Graves’ & Mean Platelet Volume
Table-I: General characteristics of Graves patients.
 Relapse group   Remission group P
 (n=30) (n=35)
Age (years) 44.3 ± 14.9 43.6 ± 14.9 0.83
Gender, F (%) 23 (76.6) 26 (74.2) 0.82
BMI (kg/m2) 25.9 ± 4.7 26.8 ± 4.7 0.44
Duration of 22. ± 7.8 16.6 ± 3.1 0.00
  ATD therapy (months)
Note: ATD- antit-hyroid drug, Values are mean ± SD.
Table-III: Comparison of laboratory values of 
groups according to disease outcome.
  At Relapse in At withdrawal P
 Relapse group in Remission
 (n=30) group (n=35)
MPV(fL) 9.2±1.3 8.0±1.0 0.00
TSH (uIU/ml) 0.05±0.08 2.0±1.0 0.00
fT3  (pmol/L)   9.7  (3.7-30) 4.7±0.5 0.00
fT4 (pmol/L) 26.3  (14-65) 13.6±1.6 0.00
Note: MPV- mean platelet volume, Values are the mean 
± SD or median (minimum–maximum).
Table-II: Comparision of laboratory values of groups at ATD withdrawal.
 Relapse group  (n=30) Remission group (n=35) P
Withdrawal MPV (fL)   8.0±1.2 8.0±1.0 0.81
Withdrawal TSH (uIU/ml) 1.5±1.0 2.0±1.0 0.03
Withdrawal fT3  (pmol/L) 4.8±1.2 4.7±0.5 0.46
Withdrawal fT4 (pmol/L) 14.8±2.9 13.6±1.6 0.04
Note: ATD- anti-thyroid drug, MPV- mean platelet volume, Values are the mean ± SD.
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times before.13,14 Platelets with higher volume are 
considered to be involved in inflammation; thus, 
MPV levels have been reported to be a useful 
biomarker of subclinical inflammation in patients 
with inflammatory diseases like Crohn’s disease 
and rheumatoid arthritis.13,15 The MPV levels are 
also known to be affected by thyroid hormone 
status. In the present study, we investigated the 
MPV levels of GD patients who relapsed and 
stayed in remission during at least six months of 
follow-up, after a minimum 12-month course of 
ATD therapy that was withdrawn when the cases 
were euthyroid. The mean MPV of the groups was 
indifferent at drug withdrawal but was significantly 
higher in the Relapse group at relapse time.
 Current medical literature covers several trials 
reporting MPV levels in different types of thyroid 
diseases. Studies investigating the relationship 
between thyroid functions and MPV levels 
demonstrate conflicting results. For example, 
Lippi and colleagues demonstrated a significant 
positive correlation between MPV and serum TSH 
values, whereas Ren et al. could not confirm the 
relationship.16,17
 In another study, Baldane and colleagues found a 
significant decrease in MPV levels of papillary thy-
roid carcinoma (PTC) patients after surgical treat-
ment, and they also noted that preoperative MPV 
levels of PTC cases were significantly higher than 
the ones with benign goiter. They suggest that MPV 
may be used as a biomarker in the diagnosis of PTC 
and may point to the role of platelets in malignant 
diseases with inflammatory backgrounds.18 
 Due to unpredictable responses, it is difficult for 
physicians to choose the optimal treatment regimen 
in GD. In Europe, Latin America and Japan, 
ATDs are considered the first choice of therapy.19 
Determining predictors of relapse following 
ATD treatment can undoubtedly improve patient 
management. We must consider the fact that several 
factors have been shown to indicate poor prognosis 
at the onset of the disease, including a large goiter 
size, severe thyroid dysfunction and high levels of 
TRAbs.12,20 There are also aberrant expression and 
secretion of several cytokines thought to be the 
predictors of prognosis. Serum levels of cytokines, 
such as IL-4, IL-6 and IL-10, are found to be higher 
in patients with refractory GD when compared 
to those in remission.21 However, the high cost 
of determining these parameters limits their use. 
Responding to the obvious need for cost effective 
and widely available tools that may predict disease 
course, we theorized that MPV would fill that void 
in the medical community.
 The higher MPV values in our Relapse group 
may be explained in several ways. The first possible 
explanation comes from a haematological point of 
view and is based on the shortened platelet survival 
that is observed in patients with hyperthyroidism. It 
is very well known that platelet size decreases with 
their age. As patients with hyperthyroidism have 
greater numbers of younger platelets, MPV levels 
will inevitably be higher than that of the euthyroid 
ones.22 Accordingly, a study comparing the MPV 
levels before and after ATD therapy has found a 
significant decrease after three weeks of ATD ther-
apy following euthyroidism. This study has clearly 
shown that platelet lifespan is significantly short-
ened in patients with hyperthyroidism, and higher 
MPV levels are therefore proposed to be metaboli-
cally, not immunologically, mediated phenomena.23 
Our second possible explanation comes from an 
immunological point of view. Higher MPV levels 
that were measured at relapse time in the Relapse 
group may be a marker of inflammatory disease 
activity. This conclusion is naturally drawn from 
the fact that the Relapse group has active GD. Our 
first explanation appears to be more valid, since the 
cases in both groups exhibited similar MPV lev-
els when they were euthyroid at ATD withdrawal 
time. The higher MPV level at relapse points to the 
shortened platelet lifespan with hyperthyroidism. 
 Our study applied strict excluding criteria in order 
to eliminate any factors that may interfere with 
MPV. While this strategy surely strengthened the 
present study, it inevitably resulted in a relatively 
low number of participants. We hope this fact will 
be appreciated by those considering our findings. 
Limitations of the study. Its retrospective design 
is one of them. The relatively short follow-up 
time after ATD withdrawal may be considered 
to be another limitation. However, knowing that 
about 75% of relapses occur during the first three 
months after drug withdrawal, we believe that our 
approach is reasonable. 
CONCLUSION
 In this study, we found higher relapse MPV in the 
Relapse group but discovered similar MPV levels in 
both groups at the point of ATD withdrawal. This 
finding may be attributed to hypermetabolism of 
hyperthyroidism rather than autoimmunity of GD. 
Further studies are needed to confirm our results.
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